Uncategorized
Aerie completes enrollment for Mercury 2 phase 3 trial of Roclatan
Enrollment has been completed for the Mercury 2 phase 3 trial of Roclatan for lowering IOP, Aerie Pharmaceuticals announced in a press release.Roclatan, a once-daily eye drop that combines Rhopressa (netarsudil ophthalmic solution) and latanoprost, is being evaluated in patients with glaucoma or ocular hypertension.